US Patent

US9163239 — Compositions and methods for modulating apolipoprotein C-III expression

Composition of Matter · Assigned to Isis Pharmaceuticals Inc · Expires 2034-05-01 · 8y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects oligomeric compounds that target apolipoprotein C-III for use in treating, preventing, or ameliorating diseases related to apolipoprotein C-III.

USPTO Abstract

Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein C-III (ApoCIII). In certain embodiments, the ApoCIII targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting ApoCIII for use in decreasing ApoCIII to treat, prevent, or ameliorate diseases, disorders or conditions related to ApoCIII. Certain diseases, disorders or conditions related to ApoCIII include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.

Drugs covered by this patent

Patent Metadata

Patent number
US9163239
Jurisdiction
US
Classification
Composition of Matter
Expires
2034-05-01
Drug substance claim
Yes
Drug product claim
No
Assignee
Isis Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.